Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei.

De Stasio G, Rajesh D, Ford JM, Daniels MJ, Erhardt RJ, Frazer BH, Tyliszczak T, Gilles MK, Conhaim RL, Howard SP, Fowler JF, Estève F, Mehta MP.

Clin Cancer Res. 2006 Jan 1;12(1):206-13.

2.
3.
4.

Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):831-8. Epub 2007 Jun 8.

PMID:
17560737
5.

Motexafin gadolinium: a possible new radiosensitiser.

Rodrigus P.

Expert Opin Investig Drugs. 2003 Jul;12(7):1205-10. Review.

PMID:
12831354
6.

Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy.

De Stasio G, Casalbore P, Pallini R, Gilbert B, Sanità F, Ciotti MT, Rosi G, Festinesi A, Larocca LM, Rinelli A, Perret D, Mogk DW, Perfetti P, Mehta MP, Mercanti D.

Cancer Res. 2001 May 15;61(10):4272-7.

7.

Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.

Hirschberg H, Wu GN, Madsen SJ.

Minim Invasive Neurosurg. 2007 Dec;50(6):318-23. doi: 10.1055/s-2007-993158.

PMID:
18210352
8.

Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.

Evens AM.

Curr Opin Oncol. 2004 Nov;16(6):576-80. Review.

PMID:
15627019
9.

Gadolinium neutron capture in glioblastoma multiforme cells.

Yasui LS, Andorf C, Schneider L, Kroc T, Lennox A, Saroja KR.

Int J Radiat Biol. 2008 Dec;84(12):1130-9. doi: 10.1080/09553000802538092.

PMID:
19061138
10.

Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.

Khuntia D, Mehta M.

Expert Rev Anticancer Ther. 2004 Dec;4(6):981-9. Review.

PMID:
15606327
11.

Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.

Miles DR, Smith JA, Phan SC, Hutcheson SJ, Renschler MF, Ford JM, Boswell GW.

J Clin Pharmacol. 2005 Mar;45(3):299-312.

PMID:
15703365
12.

Hypericin uptake: a prognostic marker for survival in high-grade glioma.

Ritz R, Müller M, Dietz K, Duffner F, Bornemann A, Roser F, Tatagiba M.

J Clin Neurosci. 2008 Jul;15(7):778-83. doi: 10.1016/j.jocn.2007.03.022. Epub 2008 Apr 3.

PMID:
18394904
13.

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D.

Expert Opin Pharmacother. 2009 Sep;10(13):2171-80. doi: 10.1517/14656560903179325.

PMID:
19640206
14.

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.

Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA.

Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):981-9.

PMID:
10571206
15.

Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent.

Bernhard EJ, Mitchell JB, Deen D, Cardell M, Rosenthal DI, Brown JM.

Cancer Res. 2000 Jan 1;60(1):86-91.

16.

Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.

Chang JE, Khuntia D, Robins HI, Mehta MP.

Clin Adv Hematol Oncol. 2007 Nov;5(11):894-902, 907-15. Review.

PMID:
18185489
17.

In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model.

Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X.

Mol Imaging Biol. 2006 Nov-Dec;8(6):315-23.

PMID:
17053862
18.

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Forouzannia A, Richards GM, Khuntia D, Mehta MP.

Expert Rev Anticancer Ther. 2007 Jun;7(6):785-94. Review.

PMID:
17555388
19.

Motexafin gadolinium in the treatment of brain metastases.

Richards GM, Mehta MP.

Expert Opin Pharmacother. 2007 Feb;8(3):351-9. Review.

PMID:
17266469
20.

Supplemental Content

Support Center